

10/523488

DT01 Rec'd PCT/PTC 03 FEB 2005

"Express Mail" mailing label number	<u>EL 832897039 US</u>
Date of Deposit	<u>FEB. 03, 2005</u>
I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. 1.10 on the date indicated above and is addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.	
Printed Name	<u>Queen Thomas</u>
Signature	<u>Queen Thomas</u>

PATENT APPLICATION
IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Grealish, Patrick F. and Rowlinson, Scott W.
For : Glycosylation Modified IL-20
Docket No. : X-15530

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

As a means of complying with the duty of disclosure, Applicants submit an "Information Disclosure Citation In An Application" on a Form PTO-1449 (modified) and provide(s) a copy of each of the listed documents] for consideration by the Examiner.

Since this Statement is being filed in accordance with 37 C.F.R. 1.97(b), Applicants submit that no additional fee is required.

Applicants request consideration of this information.

Respectfully submitted,



Gregory A. Cox
Attorney for Applicants
Registration No. 47,504
Phone: 317-277-2620

Eli Lilly and Company
Patent Division/GAC
P.O. Box 6288
Indianapolis, Indiana 46206-6288

Feb. 3, 2005

FORM PTO 1449 (modified) INFORMATION DISCLOSURE CITATION IN AN APPLICATION	Atty. Docket No. X-15530	Serial No. 10/523488
	Applicants Grealish, Patrick F. and Rowlinson, Scott W.	
	Filing Date	Group

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Pages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
	AA	US 6,486,301 B1	11-26-2002	Ebner, Reinhard, et al.	
	AB	US 6,610,286 B2	08-26-2003	Thompson, Penny, et al.	
	AC	US			
	AD	US			
	AE	US			

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ - Kind Code ⁵ (if known)				
	BA	WO 99/27103	06-03-1999	Zymogenetics, Inc.		
	BB	WO 00/12708	03-09-2000	Genentech, Inc.		
	BC	WO 02/070001 A2	09-12-2002	Eli Lilly and Company		
	BD					
	BE					
	BF					
	BG					
	BH					
	BI					
	BJ					
	BK					
	BL					

FORM PTO 1449 (modified)	Atty. Docket No.	Serial No.
	X-15530	10/523488
	Applicants	
	Grealish, Patrick F. and Rowlinson, Scott W.	
INFORMATION DISCLOSURE CITATION IN AN APPLICATION	Filing Date	Group

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s) publisher, city and/or country where published.	T ⁶
	CA	BAZAN, JF, "Structural design and molecular evolution of a cytokine receptor superfamily", Proc. Natl. Acad. Sci., 1990, pgs. 6934-6938, Vol. 87	
	CB	BLUMBERG, H, et al., "Interleukin 20: Discovery, Receptor Identification, and Role in Epidermal Function", Cell, Jan. 2001, pgs. 9-19, Vol. 104	
	CC	DUMOUTIER, L, et al., "Viral and cellular interleukin-10 (IL-10)-related cytokines: from structures to functions", Eur. Cytokine Netw., 2002, pgs. 5-15, Vol. 13, No. 2	
	CD	DUMOUTIER, L, et al., "Cutting Edge: STAT Activation By IL-19, IL-20 and mda-7 Through IL-20 Receptor Complexes of Two Types ¹ ", The Journal of Immunology, 2001, pgs. 3545-3549, Vol. 167, No. 7	
	CE	FICKENSCHER, H, et al., "The interleukin-10 family of cytokines", Trends in Immunology, Feb. 2002, pgs. 89-96, Vol. 23, No. 2	
	CF	HÖR, S, et al., "The T-cell Lymphokine Interleukin-26 Targets Epithelial Cells through the Interleukin-20 Receptor 1 and Interleukin-10 Receptor 2 Chains*", The Journal of Biological Chemistry, Aug. 2004, pgs. 33343-33351, Vol. 279, No. 32	
	CG	KOTENKO, SV, "The family of IL-10 related cytokine and their receptors: related, but to what extent?", Cytokine and Growth Factor Reviews, 2002, pgs. 223-240, Vol. 13	
	CH	LIU, L, et al., "Selective enhancement of multipotential hematopoietic progenitors in vitro and in vivo by IL-20", Nov. 2003, pgs. 3206-3209, Vol. 102, No. 9	
	CI	MOORE, KW, et al., "Interleukin-10 and the Interleukin-10 Receptor", Annu. Rev. Immunol., 2001, pgs. 683-765, Vol. 19	
	CJ	RICH, BE, et al., "Cytokines IL-20 – a new effector in skin inflammation", Current Biology, 2001, R531-R534, Vol. 11, No. 13	
	CK	WANG, M, et al., "Interleukin 24 (MDA-7/MOB-5) Signals through Two Heterodimeric Receptors, IL-22R1/IL-20R2 and IL-20R1/IL-20R2*", The Journal of Biological Chemistry, March 2002, pgs. 7341-7347, Vol. 277, No. 9	
	CL	WOLK, K, et al., "Cutting Edge: Immune Cells as Sources and Targets of the IL-10 Family Members?", The Journal of Immunology, June 2002, pgs. 5397-5402, Vol. 168, No. 11	
	CM		
Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached. Burden Hours Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case.

Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.